References in bold are published by MATHEC members
2024
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach R G, Schäfer S, Grieshaber-Bouyer R, Korganow A-S, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, and Schett G
N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917.
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
Greco R , Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden J A, Tarte K, Onida F, Sánchez-Ortega I, Burman J, Castilla Llorente C, Cervera R, Ciceri F, Doria A, Henes J, Lindsay J, Mackensen A, Muraro P A, Ricart E, Rovira M, Zuckerman T, Yakoub-Agha I and Farge D
EClinicalMedicine. 2024 Feb 10:69:102476. doi: 10.1016/j.eclinm.2024.102476. eCollection 2024 Mar.
2023
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Röhrich M, Rodon L, Deicher F, Andreeva I, Tretter T, Tykocinski L-O, Blank N, Watzl C, Schmitt A, Sauer T, Müller-Tidow C, Polke M, Heußel C P, Dreger P, Lorenz H-M, Schmitt M
Ann Rheum Dis. 2023 Dec 22:ard-2023-225174. doi: 10.1136/ard-2023-225174.
Anti-CD19 CAR T cells for refractory myasthenia gravis
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Desel C, Borie D, Motte J, Schett G, Schroers R, Gold R, Mougiakakos D
Lancet Neurol. 2023 Dec;22(12):1104-1105. doi: 10.1016/S1474-4422(23)00375-7.
CAR T cells for treating autoimmune diseases
Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S
RMD Open. 2023 Nov 23;9(4):e002907. doi: 10.1136/rmdopen-2022-002907.
CAR T-cell therapy in autoimmune diseases
Schett G, Mackensen A, Mougiakakos D
Lancet. 2023 Sep 22;S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126-1.
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
Granit V, Benatar M, Kurtoglu M, Miljković MD, Chahin N, Sahagian G, Feinberg MH, Slansky A, Vu T, Jewell CM, Singer MS, Kalayoglu MV, Howard Jr JF, Mozaffar T; MG-001 Study Team
Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1016/S1474-4422(23)00194-1.
CD19-Targeting CAR T Cells forMyositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, Seitz C, Stanger A, Schneider J, Braun C, Schmidt M, Horger M, Bornemann A, Faul C, Bethge W, Henes J, Lengerke C.
JAMA. 2023;329(24):2154-2162. doi:10.1001/jama.2023.8753
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Muzes G and Sipos F
Cells 2023, 12, 1534.https://doi.org/10.3390/ cells12111534
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol
Lalu M M, Kekre N, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Sobh M, Fergusson D A
Syst Rev. 2023; 12: 9.Published online 2023 Jan 19. doi: 10.1186/s13643-022-02158-1
After AAnti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results
Qin C,Tian DS, Zhou LQ, Shang Ke, Huang L, Dong MH, You YF, Xiao J, Xiong Y, Wang W, Pang H, Guo JJ, Cai SB, Wang D, Li CR, Zhang,M, Bu BT, Wang W.
Signal Transduct Target Ther. 2023 Jan 4;8(1):5. doi: 10.1038/s41392-022-01278-3.
2022
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary S, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici A B, Buettner C, Habenicht K.M, Winkler TH, Krönke G, Schett G.
Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5.
Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus
Kretschmann S, Völkl S, Reimann H, Krönke G, Schett G, Achenbach S , Lutzny-Geier G, Müller F, Mougiakakos D, Dingfelder J, Flamann C, Hanssens L, Gary R, Mackensen A, Aigner M
Transplant Cell Ther. 2022 Oct 12;S2666-6367(22)01699-2. doi: 10.1016/j.jtct.2022.10.004.
2021
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G.
N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725.
Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
Jin X, Xu Q,Pu C, Zhu K , Lu C, Jiang Y, Xiao L, Han Y, Lu L.
Cell Mol Immunol. 2021 Aug; 18(8): 1896–1903. doi: 10.1038/s41423-020-0472-1